Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Recurrent MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma
Interventions
BIOLOGICAL

Aldesleukin

Given IV

BIOLOGICAL

gp100 Antigen

Given SC

DRUG

Montanide ISA 51 VG

Given SC

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (19)

18015

Saint Luke's University Hospital-Bethlehem Campus, Bethlehem

20892

National Institutes of Health, Bethesda

28203

Carolinas Medical Center, Charlotte

30322

Emory University/Winship Cancer Institute, Atlanta

33805

Lakeland Regional Cancer Center, Lakeland

35294

University of Alabama at Birmingham, Birmingham

40202

The James Graham Brown Cancer Center at University of Louisville, Louisville

43210

Ohio State University Comprehensive Cancer Center, Columbus

45219

The Christ Hospital, Cincinnati

46526

IU Health Goshen Center for Cancer Care, Goshen

53215

Aurora Saint Luke's Medical Center, Milwaukee

60068

Advocate Lutheran General Hospital., Park Ridge

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

85259

Mayo Clinic in Arizona, Scottsdale

92505

Kaiser Permanente Medical Center, Riverside

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019682 - Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | Biotech Hunter | Biotech Hunter